Barclays
IMCR icon

Barclays’s Immunocore IMCR Stock Holding History

Barclays’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$959K Buy
31,673
+2,156
+7% +$73.3K ﹤0.01% 3082
2026
Q2 		$937K Sell
29,517
-1,392
-5% -$41.2K ﹤0.01% 2828
2026
Q1 		$932K Sell
30,909
-72,344
-70% -$2.34M ﹤0.01% 2802
2025
Q4 		$3.58M Sell
103,253
-3,790
-4% -$134K ﹤0.01% 2479
2025
Q3 		$3.89M Buy
107,043
+181
+0.2% +$6.15K ﹤0.01% 2388
2025
Q2 		$3.35M Sell
106,862
-228
-0.2% -$7.08K ﹤0.01% 2440
2025
Q1 		$3.18M Buy
107,090
+86,465
+419% +$2.59M ﹤0.01% 2278
2024
Q4 		$608K Buy
20,625
+19,663
+2,044% +$622K ﹤0.01% 3700
2024
Q3 		$29.9K Buy
962
+27
+3% +$982 ﹤0.01% 4842
2024
Q2 		$31.7K Sell
935
-6,813
-88% -$347K ﹤0.01% 4352
2024
Q1 		$504K Buy
7,748
+167
+2% +$11.5K ﹤0.01% 3588
2023
Q4 		$518K Sell
7,581
-57,474
-88% -$2.99M ﹤0.01% 3850
2023
Q3 		$3.38M Sell
65,055
-132,086
-67% -$7.82M ﹤0.01% 1570
2023
Q2 		$11.8M Sell
197,141
-5,843
-3% -$334K 0.01% 919
2023
Q1 		$10M Buy
202,984
+5,856
+3% +$329K ﹤0.01% 1158
2022
Q4 		$11.3M Buy
197,128
+196,456
+29,235% +$11.1M 0.01% 1147
2022
Q3 		$32K Sell
672
-104
-13% -$4.96K ﹤0.01% 3913
2022
Q2 		$29K Sell
776
-332
-30% -$10.8K ﹤0.01% 4258
2022
Q1 		$33K Buy
+1,108
New +$28K ﹤0.01% 4273

Other funds holding IMCR

Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Fulcrum Asset Management
Fulcrum Asset Management London, United Kingdom $2.14B AUM 54.66% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Commonwealth of Pennsylvania Public School Employees Retirement System
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $21.9B AUM 28.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Crossmark Global Holdings
Crossmark Global Holdings Houston, Texas $7.69B AUM 31.68% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $29.2B AUM 30.02% 1-Year Est. Return

Barclays's IMCR Position: Q3 2026 in Review

Barclays increased its Immunocore (IMCR) stake by 7.3% in Q3 2026, buying an estimated $73.3K and bringing the position to 31,673 shares worth $959K. The position accounts for ﹤0.01% of the portfolio, ranked #3082.

Barclays first reported a position in IMCR in Q1 2022 and has held it in 19 quarters since. The position peaked at $11.8M in Q2 2023. 31 funds tracked by Wall St. Rank hold IMCR as of Q3 2026.

  • Barclays held 31,673 shares of Immunocore worth $959K as of Q3 2026.
  • Barclays bought 2,156 Immunocore shares in Q3 2026, an estimated $73.3K.
  • Immunocore made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3082 holding.
  • Barclays first reported a position in Immunocore in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Immunocore position peaked at $11.8M in Q2 2023.
  • 31 funds tracked by Wall St. Rank held Immunocore as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.